US2013296264A1PendingUtilityA1

Ophthalmic compositions with improved dessication protection and retention

67
Assignee: ALCON RES LTDPriority: May 4, 2012Filed: May 3, 2013Published: Nov 7, 2013
Est. expiryMay 4, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:James W. DavisHoward Allen KetelsonElaine E. CampbellDavid L. MeadowsRekha Rangarajan
A61K 47/36A61K 47/32A61P 27/02A61P 27/04A61K 9/08A61K 47/02A61K 9/0048A61K 47/26A61K 31/728A61K 31/736A61K 47/10A61K 31/047
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An ophthalmic composition comprising 0.1 to 0.2 w/v % galactomannan, 0.05 to 0.5 w/v % hyaluronic acid, and 1.0 to 2.0 w/v % cis-diol. 
     
     
         2 . A composition according to  claim 1  comprising 0.17 to 0.18 w/v % guar, 0.13 to 0.17 w/v % sodium hyaluronate, and 1.4 w/v % sorbitol. 
     
     
         3 . A composition according to  claim 1  wherein said galactomannan is selected from the group consisting of:
 guar, hydroxylpropyl guar, and combinations thereof. 
 
     
     
         4 . A composition according to  claim 1  wherein said cis-diol is selected from the group consisting of sorbitol, mannitol, polyethylene glycols, polypropylene glycols, polyethyleneoxide-polybutyleneoxide block copolymers, and combinations thereof. 
     
     
         5 . A composition according to  claim 1  wherein said cis-diol is sorbitol or mannitol. 
     
     
         6 . A composition according to  claim 5  wherein said cis-diol is present at a concentration of about 1.4 w/v %. 
     
     
         7 . A composition according to  claim 1  wherein said borate is boric acid. 
     
     
         8 . A composition according to  claim 1  further comprising a demulcent selected from the group consisting of:
 glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, propylene glycol, polyacrylic acid, and combinations thereof. 
 
     
     
         9 . A composition according to  claim 8  wherein said demulcent is polypropylene glycol or polyethylene glycol. 
     
     
         10 . A composition according to  claim 1  further comprising a pharmaceutically active compound. 
     
     
         11 . A method for treating ophthalmic disease which comprises administering to a subject in need of such treatment a composition according to  claim 1 . 
     
     
         12 . A method according to  claim 10 , wherein the ophthalmic disease is dry eye.

Join the waitlist — get patent alerts

Track US2013296264A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.